327. Deputy William Aird asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy; and if she will make a statement on the matter. [38468/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
332. Deputy Erin McGreehan asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy. [38500/26]
354. Deputy Barry Ward asked the Minister for Health if her attention has been drawn to a campaign related to access to continuous glucose monitoring (details supplied); the actions she will take to engage with this campaign; and if she will make a statement on the matter. [38555/26]
355. Deputy Barry Ward asked the Minister for Health the position regarding any review of access to HSE supports for continuous glucose monitoring that would include those originally diagnosed with not being insulin dependent, but this diagnosis subsequently changing (details supplied); and if she will make a statement on the matter. [38556/26]
356. Deputy Barry Ward asked the Minister for Health her views on the fairness of the discrepancy in access to HSE supports for continuous glucose monitoring (details supplied); and if she will make a statement on the matter. [38557/26]
357. Deputy Michael Cahill asked the Minister for Health if she will intervene to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations (details supplied); her views on whether the current delay aligns with the 'equitable access' promised in the newly launched National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [38564/26]
243. Deputy Marie Sherlock asked the Minister for Health if there has been engagement by the corporate pharmaceutical unit in the HSE with the manufacturers of miglustat with regard to juvenile Batten disease; if such medication can be reimbursed for an individual with the life limiting condition on compassionate grounds; and if she will make a statement on the matter. [37963/26]
251. Deputy Ruairí Ó Murchú asked the Minister for Health if she will consider purchasing from source, medication for people who are subsequently reimbursed by the State for the medication when they buy it in any case; and if she will make a statement on the matter. [38052/26]
286. Deputy Barry Heneghan asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy (SMA) (details supplied); when an outcome from the HSE drugs group is expected; and if she will make a statement on the matter. [38237/26]
288. Deputy Conor Sheehan asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of Risdiplam for adults living with spinal muscular atrophy (SMA); and if she will make a statement on the matter. [38242/26]
301. Deputy Colm Burke asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy; and if she will make a statement on the matter. [38284/26]
302. Deputy Sinéad Gibney asked the Minister for Health if any policy or regulatory provision exists that restricts the ability of general practitioners to prescribe hormones to transgender patients; and, if so, the legal basis for this restriction. [38288/26]
303. Deputy Marie Sherlock asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy; and if she will make a statement on the matter. [38289/26]
987. Deputy Ken O'Flynn asked the Minister for Health the number of medicines currently awaiting a commercial proposal from a marketing authorisation holder following an invitation by the HSE; the duration each application has remained at that stage; and if she will make a statement on the matter. [36586/26]
988. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any internal monitoring system tracking delays attributable to marketing authorisation holders during the pricing and reimbursement process; and if so, to provide details. [36587/26]
989. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been carried out regarding the impact on patient access arising from the absence of statutory or administrative deadlines for the submission of commercial proposals by marketing authorisation holders. [36588/26]
990. Deputy Ken O'Flynn asked the Minister for Health whether consideration has been given to introducing statutory or regulatory timeframes governing engagement by marketing authorisation holders once invited to submit a commercial proposal to the HSE. [36589/26]
991. Deputy Ken O'Flynn asked the Minister for Health whether the Department or the HSE publishes, or intends to publish, anonymised data on delays in the pricing and reimbursement process attributable to marketing authorisation holders. [36590/26]
992. Deputy Ken O'Flynn asked the Minister for Health whether any escalation mechanism exists where a pricing and reimbursement application remains inactive for an extended period due to the absence of a commercial proposal from a marketing authorisation holder. [36591/26]
993. Deputy Ken O'Flynn asked the Minister for Health whether the absence of formal timelines for commercial engagement by marketing authorisation holders has been identified as a governance, transparency or patient-access risk within the medicines reimbursement system. [36592/26]
994. Deputy Ken O'Flynn asked the Minister for Health whether any comparative review has been carried out examining how other EU jurisdictions manage delays by marketing authorisation holders during medicines pricing and reimbursement negotiations. [36593/26]
1030. Deputy Ken O'Flynn asked the Minister for Health the rationale and assessment process underpinning the 2022 reimbursement price uplift granted to Steri-neb Salamol 2.5mg/2.5ml. [36754/26]
1031. Deputy Ken O'Flynn asked the Minister for Health whether any cost-effectiveness, inflationary, supply-chain or market-availability assessment was undertaken prior to the Steri-neb Salamol price uplift. [36755/26]
1032. Deputy Ken O'Flynn asked the Minister for Health how many medicinal products received reimbursement price uplifts under PCRS arrangements in each year from 2020 to 2026. [36756/26]
1072. Deputy Ken O'Flynn asked the Minister for Health whether the primary care reimbursement service maintains data on incorrect or overturned claim rejections; and, if so, to provide the figures for 2024 and 2025. [36913/26]